In contrast, Trx has demonstrated in numerous studies that it can attenuate emphysematous alterations in COPD animal models by lowering CS-induced oxidative stress and inflammation, even in mice that corticosteroids cannot control. Here, TXN is linked to chronic obstructive pulmonary disease.